Clinical trial · Interventional
Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers
Celecoxib for Chemoprevention of Primary Lung Cancer
NCT00020878CI-TRIAL-00046371completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Celecoxib may be effective in preventing lung cancer in tobacco smokers. PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing non-small cell lung cancer in tobacco smokers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| celecoxib | Drug | Celecoxib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Study
- description
- See intervention description.
- interventionNames
- Drug: celecoxib
Primary outcomes (2)
- measure
- Evaluate the expression of Cox-2 and PGE2 in the lungs of tobacco smokers.
- timeFrame
- 1 year
- measure
- Evaluate the capacity for an oral Cox-2 inhibitor (Celecoxib) to suppress the intrapulmonary formation of PGE2
- timeFrame
- 1 year
Secondary outcomes (2)
- measure
- Determine the effects of Cox-2 inhibition on biomarkers of field cancerization on histopathologic abnormalities in patients at risk for primary NSCLC
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 45 * Smoked \> 20 pack years Exclusion Criteria: * Concurrent use of NSAIDs * Hypersensitivity to celecoxib * Documented allergic-type reaction to sulfonamides * History of allergic reaction, urticaria or asthma to aspirin or other NSAIDs * History of liver dysfunction * Hypertension or cardiac conditions aggravated by fluid retention and edema * Previous history of gastrointestinal ulceration, bleeding, or perforation * Renal dysfunction * End stage respiratory disease * Unstable angina * Other malignancy * Pregnancy * Concurrent use of medication known to alter or be affected by alteration of the hepatic p450 2C9 and 2D6 enzymes * Patents with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow up schedule
References
Publications (0)
Data not yet available
No reference posted for this study.